COMPANY OVERVIEW

Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.

---

LOCATION

Lexington, MA, USA

---

THERAPEUTIC AREAS

Fibrotic DIsease

---

WEBSITE

https://www.promedior.com

---

CAREER WEBSITE

https://www.promedior.com/careers/overview.html

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Feb 13, 2020

Promedior Announces Completion of Acquisition by Roche

Nov 15, 2019

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Jun 17, 2019

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

May 20, 2019

Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

Mar 26, 2019

Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

For More Press Releases

---